AIP
BHVN

ARS Investment Partners’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

ARS Investment Partners’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-45,892
Closed -$6.94M – 190
2022
Q3 		$6.94M Buy
45,892
+41,175
+873% +$6.1M 0.95% 31
2022
Q2 		$687K Sell
4,717
-428,407
-99% -$54.7M 0.09% 85
2022
Q1 		$51.4M Sell
433,124
-30,268
-7% -$3.78M 4.95% 2
2021
Q4 		$63.9M Sell
463,392
-3,276
-0.7% -$417K 5.87% 2
2021
Q3 		$64.8M Sell
466,668
-91,618
-16% -$11.4M 6.49% 2
2021
Q2 		$54.2M Sell
558,286
-3,156
-0.6% -$256K 5.52% 2
2021
Q1 		$38.4M Buy
561,442
+2,005
+0.4% +$162K 4.46% 2
2020
Q4 		$47.9M Sell
559,437
-137
-0% -$11.6K 5.9% 2
2020
Q3 		$36.4M Sell
559,574
-45,668
-8% -$2.99M 5.72% 3
2020
Q2 		$44.2M Buy
605,242
+2,206
+0.4% +$117K 8.33% 2
2020
Q1 		$20.5M Buy
603,036
+17,747
+3% +$811K 4.95% 4
2019
Q4 		$31.9M Buy
585,289
+14,481
+3% +$717K 5.36% 2
2019
Q3 		$23.8M Buy
570,808
+26,585
+5% +$1.12M 4.28% 2
2019
Q2 		$23.8M Buy
544,223
+80,096
+17% +$4.52M 4.01% 3
2019
Q1 		$23.9M Buy
464,127
+60,856
+15% +$2.63M 4.32% 3
2018
Q4 		$14.9M Sell
403,271
-12,284
-3% -$443K 3.16% 12
2018
Q3 		$15.6M Buy
415,555
+25,666
+7% +$944K 2.42% 16
2018
Q2 		$15.4M Buy
389,889
+129,634
+50% +$4.11M 2.46% 17
2018
Q1 		$6.7M Buy
260,255
+153,943
+145% +$4.6M 0.82% 41
2017
Q4 		$2.87M Buy
+106,312
New +$2.93M 0.35% 57

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

ARS Investment Partners's BHVN Position: Q4 2022 in Review

ARS Investment Partners sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 45,892 shares — an estimated $6.94M sold.

ARS Investment Partners first reported a position in BHVN in Q4 2017 and held it in 20 quarters. The position peaked at $64.8M in Q3 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • ARS Investment Partners reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • ARS Investment Partners sold 45,892 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $6.94M.
  • ARS Investment Partners first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2017 and held it in 20 quarters.
  • ARS Investment Partners's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $64.8M in Q3 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on ARS Investment Partners's 13F filing for Q4 2022, filed 25 Jan 2023.